Dr
Thomas
Olbrich

Senior European Patent Attorney

Newcastle Office

Engineering

Telephone. +44(0) 191 205 8360
Mobile. +44(0) 771 744 0324
Email. [email protected]

Experience

Tom is a PHD physicist with a real passion for most technologies and innovation. Tom's extensive experience covers a wide spectrum of technologies, from relatively simple concepts, such as shoes, floating platforms and power tools, to semiconductor and superconductor systems, as well as, computer implemented applications and medical devices. Tom has considerable experience (15+ years) in patent drafting and European, as well as worldwide patent prosecution.

Tom's areas of expertise include engineering, electronics and physics related technology in general, and in particular, medical devices, sporting goods, semiconductors and ICs, power tools, automotive fasteners, appliances, as well as, offshore and oil & gas technology (e.g. downhole tools, seismic interpretation software).

After spending a few years in the special military forces in his native Germany, competing i.a. in athletics, biathlon and bobsleigh, Tom went to study Applied Physics (MSc) at the University of Applied Science in Munich and Physics (BSc) at Nottingham Trent University. In order to further his studies, he then completed a PhD in Medical Physics at the University of Newcastle upon Tyne.

In 2005, he began working towards becoming a Patent and Trade Mark attorney. He has since gained extensive experience working with four leading European patent firms. He is known for a very personal approach and a high quality of work.

Qualifications

Patent Attorney

European


BSC

Physics

MSC

Applied Physics

PHD

Medical Physics

Publications

Northern Insight Article

View publication online

CSR

Tom is involved with mentoring Trainees in patent drafting.

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 19th May 2022

HGF Complete webinar: comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

HGF is hosting a series of HGF Complete webinars this Spring. Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.